{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T19:27:44Z","timestamp":1715801264326},"reference-count":29,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":3594,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Single interventions in chronic fatigue syndrome have shown only limited effectiveness, with few studies of comprehensive treatment programmes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To examine the effect of a comprehensive cognitive-behavioural treatment (CCBT) programme compared with placebo-controlled mirtazapine medication in patients with chronic fatigue, and to study the effect of combined medication and CCBT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A three-armed randomised clinical trial of mirtazapine, placebo and a CCBT programme was conducted to investigate treatment effect in a patient group (<jats:italic>n<\/jats:italic>=72) with chronic fatigue referred to a specialist clinic. The CCBT programme was compared with mirtazapine or placebo therapy for 12 weeks, followed by 12 weeks treatment with a mixed crossover-combination design. Assessments were done at 12 weeks and 24 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By 12 weeks the treatment effect was significantly better in the group initially receiving CCBT, as assessed with the Fatigue Scale (<jats:italic>P<\/jats:italic>=0.014) and the Clinical Global Impression Scale (<jats:italic>P<\/jats:italic>=0.001). By 24 weeks the treatment group initially receiving CCBT for 12 weeks followed by mirtazapine for 12 weeks showed significant improvement compared with the other treatment groups on the Fatigue Scale (<jats:italic>P<\/jats:italic> &lt; 0.001) and the Clinical Global Impression Scale (<jats:italic>P<\/jats:italic>=0.002). Secondary outcome measures showed overall improvement with no significant difference between treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Multimodal interventions may have positive treatment effects in chronic fatigue syndrome. Sequence of interventions seem to be of importance.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.bp.106.031815","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T19:33:37Z","timestamp":1204313617000},"page":"217-223","source":"Crossref","is-referenced-by-count":21,"title":["Cognitive-behavioural therapy <i>v<\/i>. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial"],"prefix":"10.1192","volume":"192","author":[{"given":"Bjarte","family":"Stubhaug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein Atle","family":"Lie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Ursin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege R.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000234260_ref15","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research","year":"1993"},{"key":"S0007125000234260_ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000288128"},{"key":"S0007125000234260_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00098-5"},{"key":"S0007125000234260_ref3","article-title":"A report \u2013 chronic fatigue syndrome: guidelines for research","volume":"84","author":"Sharpe","year":"1991","journal-title":"J R Soc Med"},{"key":"S0007125000234260_ref21","volume-title":"SF-36 Physical and Mental Health Summary Scales: A Manual for Users of ver 1","author":"Ware","year":"2001"},{"key":"S0007125000234260_ref23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000234260_ref6","article-title":"Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome\/myalgic encephalomyelitis: an updated systematic review","volume":"99","author":"Chambers","year":"2006","journal-title":"J R Soc Med"},{"key":"S0007125000234260_ref1","article-title":"Neurasthenia, or nervous exhaustion","volume":"3","author":"Beard","year":"1869","journal-title":"Boston Med Surg J"},{"key":"S0007125000234260_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(93)90081-P"},{"key":"S0007125000234260_ref27","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"S0007125000234260_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00882-9"},{"key":"S0007125000234260_ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"S0007125000234260_ref2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-3-387"},{"key":"S0007125000234260_ref25","doi-asserted-by":"publisher","DOI":"10.1080\/08870440290001494"},{"key":"S0007125000234260_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/25.6.666"},{"key":"S0007125000234260_ref14","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-827172"},{"key":"S0007125000234260_ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199704001-00003"},{"key":"S0007125000234260_ref16","volume-title":"Schedules for Clinical Assessment in Neuropsychiatry (SCAN)","year":"1992"},{"key":"S0007125000234260_ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.11.1360"},{"key":"S0007125000234260_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2005.04.011"},{"key":"S0007125000234260_ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.156.4.534"},{"key":"S0007125000234260_ref26","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1954.7.2.218"},{"key":"S0007125000234260_ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957040-00010"},{"key":"S0007125000234260_ref13","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80486"},{"key":"S0007125000234260_ref19","volume-title":"SF-36 Health Survey Manual and Interpretation Guide","author":"Ware","year":"2000"},{"key":"S0007125000234260_ref4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-12-199412150-00009"},{"key":"S0007125000234260_ref22","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0007125000234260_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-3991(02)00040-X"},{"key":"S0007125000234260_ref18","doi-asserted-by":"publisher","DOI":"10.1177\/14034948990270010401"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000234260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T20:33:30Z","timestamp":1556656410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000234260\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0007125000234260"],"URL":"https:\/\/doi.org\/10.1192\/bjp.bp.106.031815","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}